Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Freeline Therapeutics Holdings plc FRLN NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • GB • USD

SharesGrow Score
33/100
1/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Freeline Therapeutics Holdings plc (FRLN) — Analyst outlook / Analyst consensus target is. Based on 7 analyst ratings, the consensus is bullish — 2 Buy, 5 Hold.

FRLN Analyst Ratings

Hold
7
Ratings
2 Buy
5 Hold
Based on 7 analysts giving stock ratings to Freeline Therapeutics Holdings plc in the past 3 months
Rating breakdown
Buy
2 29%
Hold
5 71%
29%
Buy
2 analysts
71%
Hold
5 analysts
0%
Sell
0 analysts

People Also View

VECT
VECT
VectivBio Holding AG
$16.87
+0.12%
 IMMX
IMMX
Immix Biopharma, Inc.
$9.85
+1.65%
 SONN
SONN
Sonnet BioTherapeutics Holdings, Inc.
$1.26
-59.35%
 AVRO
AVRO
AVROBIO, Inc.
$1.40
-1.41%
 ZVSA
ZVSA
ZyVersa Therapeutics, Inc.
$0.19
-8.57%
 CNSP
CNSP
CNS Pharmaceuticals, Inc.
$2.64
+5.18%
 HEPA
HEPA
Hepion Pharmaceuticals, Inc.
$0.05
+18.52%
 NAVB
NAVB
Navidea Biopharmaceuticals, Inc.
$0.00
0.00%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message